• Vito Andrea Capozzi, Elisa Scarpelli, Giulia Armano, Luciano Monfardini, Angela Celardo, Gaetano Maria Munno, Nicola Fortunato, Primo Vagnetti, Maria Teresa Schettino, Giulia Grassini, Domenico Labriola, Carla Loreto, Marco Torella, and Stefano Cianci.
• Department of Medicine and Surgery, University Hospital of Parma, 43125 Parma, Italy.
• Medicina (Kaunas). 2022 Apr 17; 58 (4).

AbstractBackground and Objectives: Since the Food and Drug Administration's (FDA) approval in 2005, the application of robotic surgery (RS) in gynecology has been adopted all over the world. This study aimed to provide an update on RS in benign gynecological pathology by reporting the scientific recommendations and high-value scientific literature available to date. Materials and Methods: A systematic review of the literature was performed. Prospective randomized clinical trials (RCT) and large retrospective trials were included in the present review. Results: Twenty-two studies were considered eligible for the review: eight studies regarding robotic myomectomy, five studies on robotic hysterectomy, five studies about RS in endometriosis treatment, and four studies on robotic pelvic organ prolapse (POP) treatment. Overall, 12 RCT and 10 retrospective studies were included in the analysis. In total 269,728 patients were enrolled, 1721 in the myomectomy group, 265,100 in the hysterectomy group, 1527 in the endometriosis surgical treatment group, and 1380 patients received treatment for POP. Conclusions: Currently, a minimally invasive approach is suggested in benign gynecological pathologies. According to the available evidence, RS has comparable clinical outcomes compared to laparoscopy (LPS). RS allowed a growing number of patients to gain access to MIS and benefit from a minimally invasive treatment, due to a flattened learning curve and enhanced dexterity and visualization.

15 keywords...

hide…